Cyclophosphamide-based combination therapies for autoimmunity
- First Online:
- Cite this article as:
- Perini, P., Calabrese, M., Rinaldi, L. et al. Neurol Sci (2008) 29(Suppl 2): 233. doi:10.1007/s10072-008-0947-9
- 96 Downloads
Immunomodulatory agent (IMA)-unresponsive multiple sclerosis (MS) can quickly evolve to a dramatic and irreversible disability. Treating these patients with appropriate immunosuppressive therapies can be a chance to arrest disease activity and progression. Cyclophosphamide (Cyc)-based intense immunosuppression has been successfully used to treat rapidly deteriorating, IMA-refractory MS patients. Therapeutic protocols combining Cyc and interferon beta (IFNβ) have also been successfully applied to treat IFNβ-unresponsive MS. The association of Cyc with other immunomodulatory drugs or monoclonal antibodies is currently being investigated in clinical trials aimed at treating severe forms of autoimmune diseases.